Human trials begin for Novavax's coronavirus vaccine

Biotechnology company Novavax rolled out its first human trials for its coronavirus vaccine on Tuesday.

Novavax already tested its vaccine on animals in low doses and found it successful, Axios notes. So the Maryland-based company will inject 131 volunteers in the Australian cities of Melbourne and Brisbane, with results of the clinical trial expected to be made public in July.

Phase 1 of the trial is a "randomized, observer-blinded, placebo-controlled trial" that assesses two different dosage sizes of the vaccine among healthy participants age 18 to 59, Novavax said in a press release. If that first phase goes well, Novavax said it expects a second phase to begin "promptly." That second phase will be conducted across several different countries, including the U.S., and across a broader age range.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Novavax shares spiked when markets reopened Tuesday after the holiday weekend, up from $46.11 per share to $54.20. Novavax is among several pharmaceutical companies racing to develop coronavirus vaccines, with Pfizer and Moderna launching human trials earlier this month.